TRITON and Beyond: New Insights into the Profile of Prasugrel

Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Jakubowski, Joseph A, Riesmeyer, Jeffrey S, Close, Sandra L, Leishman, Amy G, Erlinge, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440581/
https://www.ncbi.nlm.nih.gov/pubmed/21883999
http://dx.doi.org/10.1111/j.1755-5922.2011.00263.x
_version_ 1782243181532807168
author Jakubowski, Joseph A
Riesmeyer, Jeffrey S
Close, Sandra L
Leishman, Amy G
Erlinge, David
author_facet Jakubowski, Joseph A
Riesmeyer, Jeffrey S
Close, Sandra L
Leishman, Amy G
Erlinge, David
author_sort Jakubowski, Joseph A
collection PubMed
description Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.
format Online
Article
Text
id pubmed-3440581
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-34405812012-09-13 TRITON and Beyond: New Insights into the Profile of Prasugrel Jakubowski, Joseph A Riesmeyer, Jeffrey S Close, Sandra L Leishman, Amy G Erlinge, David Cardiovasc Ther Review Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure. Blackwell Publishing Ltd 2012-08 2011-02-17 /pmc/articles/PMC3440581/ /pubmed/21883999 http://dx.doi.org/10.1111/j.1755-5922.2011.00263.x Text en Copyright © 2012 Blackwell Publishing Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Review
Jakubowski, Joseph A
Riesmeyer, Jeffrey S
Close, Sandra L
Leishman, Amy G
Erlinge, David
TRITON and Beyond: New Insights into the Profile of Prasugrel
title TRITON and Beyond: New Insights into the Profile of Prasugrel
title_full TRITON and Beyond: New Insights into the Profile of Prasugrel
title_fullStr TRITON and Beyond: New Insights into the Profile of Prasugrel
title_full_unstemmed TRITON and Beyond: New Insights into the Profile of Prasugrel
title_short TRITON and Beyond: New Insights into the Profile of Prasugrel
title_sort triton and beyond: new insights into the profile of prasugrel
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440581/
https://www.ncbi.nlm.nih.gov/pubmed/21883999
http://dx.doi.org/10.1111/j.1755-5922.2011.00263.x
work_keys_str_mv AT jakubowskijosepha tritonandbeyondnewinsightsintotheprofileofprasugrel
AT riesmeyerjeffreys tritonandbeyondnewinsightsintotheprofileofprasugrel
AT closesandral tritonandbeyondnewinsightsintotheprofileofprasugrel
AT leishmanamyg tritonandbeyondnewinsightsintotheprofileofprasugrel
AT erlingedavid tritonandbeyondnewinsightsintotheprofileofprasugrel

Ejemplares similares